Cover Image

Empagliflozin improves kidney outcomes in patients with or without heart Failure

Background: In EMPA-REG OUTCOME (Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients) empagliflozin significantly reduced the risk of cardiovascular and kidney out...

Saved in:
Bibliographic Details
Main Authors: Butler, Javed (Author) , Zannad, Faiez (Author) , Fitchett, David (Author) , Zinman, Bernard (Author) , Koitka-Weber, Audrey (Author) , Eynatten, Maximilian von (Author) , Zwiener, Isabella (Author) , George, Jyothis (Author) , Brückmann, Martina (Author) , Cheung, Alfred K. (Author) , Wanner, Christoph (Author)
Format: Article (Journal)
Language:English
Published: 5 Jun 2019
In: Circulation. Heart failure
Year: 2019, Volume: 12, Issue: 6
ISSN:1941-3297
DOI:10.1161/CIRCHEARTFAILURE.118.005875
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1161/CIRCHEARTFAILURE.118.005875
Verlag: https://www.ahajournals.org/doi/abs/10.1161/CIRCHEARTFAILURE.118.005875
Get full text
Author Notes:Javed Butler, Faiez Zannad, David Fitchett, Bernard Zinman, Audrey Koitka-Weber, Maximilian von Eynatten, Isabella Zwiener, Jyothis George, Martina Brueckmann, Alfred K. Cheung, Christoph Wanner
Description
Summary:Background: In EMPA-REG OUTCOME (Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients) empagliflozin significantly reduced the risk of cardiovascular and kidney out...
Item Description:Originally published 5 Jun 2019
Gesehen am 19.02.2020
Physical Description:Online Resource
ISSN:1941-3297
DOI:10.1161/CIRCHEARTFAILURE.118.005875

Similar Items